2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Uterine Cervical Neoplasms
10
Neoplasms
9
Breast Neoplasms
9
Colorectal Neoplasms
8
Lung Neoplasms
5
Papillomavirus Infections
3
Uterine Cervical Dysplasia
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Heart Diseases
2
HIV Infections
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
End Stage Liver Disease
2
the Rate of Participation in Screening for PBC
1
Warts
1
Venous Thromboembolism
1
Uterine Cervical Diseases
1
Urinary Bladder Neoplasms
1
Tinea
1
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Skin Neoplasms
1
Retinoblastoma
1
Radiation Injuries
1
Pulmonary Atelectasis
1
Postural Orthostatic Tachycardia Syndrome
1
Postoperative Complications
1
Interventions
Cisplatin
161
Fluorouracil
135
Paclitaxel
127
Radiotherapy
125
Oxaliplatin
88
Carboplatin
72
Docetaxel
71
Irinotecan
60
pembrolizumab
57
Leucovorin
57
Capecitabine
57
Radiation
48
Esophagectomy
44
Surgical Procedures, Operative
42
Drug Therapy
38
Neoadjuvant Therapy
28
Cetuximab
25
Nivolumab
24
Bevacizumab
21
camrelizumab
20
Trastuzumab
20
S 1 (combination)
19
Chemoradiotherapy
19
Magnetic Resonance Spectroscopy
18
Epirubicin
16
Albumin-Bound Paclitaxel
16
Blood Specimen Collection
15
tislelizumab
14
Taxes
14
Radiotherapy, Intensity-Modulated
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Mass Screening
×
Clear all
NCT06335966
2026-03-17
BEST-RPP
OHSU Knight Cancer Institute
Active not recruiting
110 enrolled
NCT03461341
2020-03-26
ENSURE
St. James's Hospital, Ireland
Completed
3,000 enrolled